Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

Li Shen, Ashley Orillion, Roberto Pili

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


HDAC inhibitors (HDACIs) are anticancer agents being developed in preclinical and clinical settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins. Most HDACIs in clinical development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented. Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies. Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system. In addition, we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different experimental settings and the target immune cell populations.

Original languageEnglish (US)
Pages (from-to)415-428
Number of pages14
Issue number3
StatePublished - Mar 2016
Externally publishedYes


  • Foxp3
  • Tregs
  • antigen-presenting cells
  • cancer immunotherapy
  • histone deacetylase inhibitor
  • immunomodulation
  • inflammatory cytokines
  • myeloid-derived suppressor cells
  • tumor associated macrophage

ASJC Scopus subject areas

  • Genetics
  • Cancer Research


Dive into the research topics of 'Histone deacetylase inhibitors as immunomodulators in cancer therapeutics'. Together they form a unique fingerprint.

Cite this